PTEN and PTEN hamartoma tumor syndrome: The 2015 ATA management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer also reference PTEN in concurrence with PHTS, and do not utilize molecular markers as inclusion or exclusion criteria for active surveillance [28].